Is GRAC undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of GRAC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate GRAC's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate GRAC's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for GRAC?
Key metric: As GRAC barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.
The above table shows the Price to Book ratio for GRAC. This is calculated by dividing GRAC's market cap by their current
book value.
What is GRAC's PB Ratio?
PB Ratio
33.3x
Book
₪2.01m
Market Cap
₪66.69m
GRAC key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Price-To-Book vs Industry: GRAC is expensive based on its Price-To-Book Ratio (33.3x) compared to the Asian Biotechs industry average (2.7x).
Price to Book Ratio vs Fair Ratio
What is GRAC's PB Ratio
compared to its
Fair PB Ratio?
This is the expected PB Ratio taking into
account the company's forecast earnings growth, profit margins
and other risk factors.
GRAC PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio
33.3x
Fair PB Ratio
n/a
Price-To-Book vs Fair Ratio: Insufficient data to calculate GRAC's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.